search
Back to results

Improving Learning-based Treatment of Cocaine Dependence With Medication

Primary Purpose

COCAINE-RELATED DISORDERS

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
d-cycloserine
sugar pill
Sponsored by
Johns Hopkins University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for COCAINE-RELATED DISORDERS

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 18-60 years of age (> 60 due to age-related effects on cognitive functioning)
  • Satisfy DSM-IV criteria for cocaine dependence (primarily crack)
  • Able to complete all study measures
  • Currently seeking treatment for cocaine dependence

Exclusion Criteria:

  • Meets DSM-IV criteria for dependence on a drug other than cocaine or nicotine (may meet abuse criteria for other drugs)
  • Pregnant, breast feeding, or planning to become pregnant within 3 months
  • If female, do not agree to use an effective means of birth control during the course of treatment (via phone screen)
  • History of seizure disorder, severe hepatic impairment, porphyria, serious head trauma, dementia, or significant cognitive impairment
  • Diagnosis of current major psychiatric disorder besides substance dependence or abuse
  • Reported use of DCS in the past year
  • Illiteracy, as will be determined during in-person screening
  • Concurrently prescribed or using ethionamide or isoniazid (both used to treat tuberculosis)
  • Positive urine result for opioids at screening interview

Sites / Locations

  • Behavioral Pharmacology Research Unit

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

50 mg d-cycloserine

Sugar pill

Arm Description

active drug condition

Inactive placebo

Outcomes

Primary Outcome Measures

Urinalysis Benzoylecgonine (Cocaine Metabolite)(ng/ml)
The primary outcome for this study will be post-treatment continuous abstinence, as assessed by urinalysis results
Medication Side-effects
self-report of medication side effects (Units of Measure is the count of specific reported effects)

Secondary Outcome Measures

Learning Task by Itami and Uno

Full Information

First Posted
January 30, 2012
Last Updated
December 22, 2016
Sponsor
Johns Hopkins University
Collaborators
National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT01526538
Brief Title
Improving Learning-based Treatment of Cocaine Dependence With Medication
Official Title
Improving Learning-based Treatment of Cocaine Dependence With Medication
Study Type
Interventional

2. Study Status

Record Verification Date
December 2016
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
March 2013 (Actual)
Study Completion Date
March 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Johns Hopkins University
Collaborators
National Institute on Drug Abuse (NIDA)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will test the efficacy of d-cycloserine in enhancing response to learning-based treatment for cocaine dependence, specifically contingency management.
Detailed Description
Cocaine dependence is a public health problem with substantial morbidity, however no effective pharmacotherapy for cocaine dependence has been approved by the FDA. Unlike previous medication studies that have sought to pharmacologically reduce cocaine reinforcement, seeking or craving, this exploratory clinical trial will test d-cycloserine (DCS) for its ability to improve learning-based behavioral treatment of cocaine dependence. DCS is an NMDA partial agonist that has been shown to robustly improve learning in preclinical models, including extinction of cocaine conditioned place preference and blockade of cocaine reacquisition, and to improve extinction-learning based exposure therapy for multiple anxiety disorders. This Phase II clinical trial will investigate the pharmacological (DCS) enhancement of a behavioral treatment combining contingency management (CM) and novel home-environment exposure therapy sessions for cocaine dependence. High magnitude CM incentives will be used to promote the cocaine abstinence necessary for extinction in home-based exposure sessions. Participants will be randomized into 2 groups: 1. CM with placebo (CM+PL), and 2. CM with DCS (CM+DCS). For 19 days after group assignment, participants will report to the laboratory 3 times per week (Mon, Wed, Fri) to provide urine samples, receive contingent vouchers, and complete assessments of drug use, craving, mood, withdrawal, and quit self-efficacy. DCS (50 mg) or placebo will be administered on Mon, Wed and Fri study visits (at the end of the lab visit before returning to the home environment for exposure sessions during the time of DCS action). Follow-up visits will be conducted at 1 week, 1 month, and 3 months post-CM completion, during which time measures of drug use (self-reported and urinalysis), craving, mood, and withdrawal will be obtained. Comparison of continuous abstinence post-CM between the groups will be the primary outcome measure. During an initial laboratory session, a battery of learning/cognitive tasks will test for forms of learning/cognition enhanced by DCS that might contribute to the treatment effect. This project will test the efficacy of a novel intervention for cocaine dependence that was developed based on a known efficacious cocaine dependence treatment (CM), principles of extinction learning theory, and a medication shown to improve preclinical learning in general, including extinction of cocaine conditioning, and clinical learning-based exposure treatment of anxiety disorders. The study may indicate cost effective additions (home exposure sessions and DCS) to extend CM benefit after the removal of contingencies, and therefore may increase the dissemination of CM in community settings.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COCAINE-RELATED DISORDERS

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
52 (Actual)

8. Arms, Groups, and Interventions

Arm Title
50 mg d-cycloserine
Arm Type
Experimental
Arm Description
active drug condition
Arm Title
Sugar pill
Arm Type
Placebo Comparator
Arm Description
Inactive placebo
Intervention Type
Drug
Intervention Name(s)
d-cycloserine
Intervention Description
50 mg d-cycloserine
Intervention Type
Drug
Intervention Name(s)
sugar pill
Intervention Description
placebo
Primary Outcome Measure Information:
Title
Urinalysis Benzoylecgonine (Cocaine Metabolite)(ng/ml)
Description
The primary outcome for this study will be post-treatment continuous abstinence, as assessed by urinalysis results
Time Frame
1 month post-treatment
Title
Medication Side-effects
Description
self-report of medication side effects (Units of Measure is the count of specific reported effects)
Time Frame
1 month post-treatment.
Secondary Outcome Measure Information:
Title
Learning Task by Itami and Uno
Time Frame
At the baseline laboratory visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 18-60 years of age (> 60 due to age-related effects on cognitive functioning) Satisfy DSM-IV criteria for cocaine dependence (primarily crack) Able to complete all study measures Currently seeking treatment for cocaine dependence Exclusion Criteria: Meets DSM-IV criteria for dependence on a drug other than cocaine or nicotine (may meet abuse criteria for other drugs) Pregnant, breast feeding, or planning to become pregnant within 3 months If female, do not agree to use an effective means of birth control during the course of treatment (via phone screen) History of seizure disorder, severe hepatic impairment, porphyria, serious head trauma, dementia, or significant cognitive impairment Diagnosis of current major psychiatric disorder besides substance dependence or abuse Reported use of DCS in the past year Illiteracy, as will be determined during in-person screening Concurrently prescribed or using ethionamide or isoniazid (both used to treat tuberculosis) Positive urine result for opioids at screening interview
Facility Information:
Facility Name
Behavioral Pharmacology Research Unit
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
212124
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
31368770
Citation
Johnson MW, Bruner NR, Johnson PS, Silverman K, Berry MS. Randomized controlled trial of d-cycloserine in cocaine dependence: Effects on contingency management and cue-induced cocaine craving in a naturalistic setting. Exp Clin Psychopharmacol. 2020 Apr;28(2):157-168. doi: 10.1037/pha0000306. Epub 2019 Aug 1.
Results Reference
derived

Learn more about this trial

Improving Learning-based Treatment of Cocaine Dependence With Medication

We'll reach out to this number within 24 hrs